Log in to search using one of your social media accounts:

 

Algorithm Picks Relevant Variables Variables help predict survivability with myelodysplastic syndromes

Aziz Nazha, MD from the Cleveland Clinic discusses algorithm picks relevant variables and variables help predict survivability with myelodysplastic syndromes at the 2017 American Society of Hematology... Author: ASHReport Added: 01/11/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts

Related Links:

Background: Therapeutic drug monitoring (TDM) of posaconazole is usually performed 1 week after starting the drug because of its long half-life. However, previous studies showed that measuring the posaconazole plasma concentration (PPC) on day 3 is effective for predicting steady-state levels. The purpose of this study was to evaluate the relevance of early TDM (day 3) of posaconazole for achieving an optimal PPC. Methods: This prospective study was conducted from September 2014 to August 2016. A total of 148 patients with acute myeloid leukemia or myelodysplastic syndromes received a 200 mg posaconazole oral suspensi...
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Original Article Source Type: research
Successful treatment of a patient with myelodysplastic syndrome accompanied by pyoderma gangrenosum and Behçet's disease using allogeneic stem cell transplantation. Blood Res. 2017 Dec;52(4):319-321 Authors: Lee SS, Ahn JS, Yun SJ, Park DJ PMID: 29333411 [PubMed]
Source: Blood Research - Category: Hematology Tags: Blood Res Source Type: research
Authors: Lee JY, Cho HJ PMID: 29333398 [PubMed]
Source: Blood Research - Category: Hematology Tags: Blood Res Source Type: research
Authors: Nenova I, Grudeva-Popova J Abstract The growing number of successfully cured cancer patients has created a new field in oncogenesis. The life expectancy of such patients has increased, however this favorable event may create enough time for epigenetic events to occur which can cause a new carcinognic event, i.e. a secondary malignancy. The terms in use are second primary malignancies as well as therapy-related neoplasms in case the treatment of the first neoplasm is a direct cause. Second primary malignancies can be hematological neoplasms or solid tumors, with solid tumors having higher frequency. Hematol...
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Blasts Under 10 Percent of Bone Marrow Nucleated Cells;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive ;   Cytogenetic Abnormality;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Pancytopenia;   Refractory Anemia Interventions: &nb...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionsMass-forming extramedullary hematopoiesis is rare; however, our report emphasizes that it needs to be considered in the initial differential diagnosis of hepatic lesions arising in the setting of bone marrow disorders. We also show that in the setting of diffuse hepatic iron overload, tumefactive extramedullary hematopoiesis appeared isointense to background liver on T2* gradient-echo sequence, while adenoma, hepatoma, and hepatic metastasis appear hyperintense. Thus, T2*-weighted gradient-echo sequence may have a potential role in the imaging diagnosis of mass-forming hepatic extramedullary hematopoiesis arisin...
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
Background: Therapeutic drug monitoring (TDM) of posaconazole is usually performed 1 week after starting the drug because of its long half-life. However, previous studies showed that measuring the posaconazole plasma concentration (PPC) on day 3 is effective for predicting steady-state levels. The purpose of this study was to evaluate the relevance of early TDM (day 3) of posaconazole for achieving an optimal PPC. Methods: This prospective study was conducted from September 2014 to August 2016. A total of 148 patients with acute myeloid leukemia or myelodysplastic syndromes received a 200 mg posaconazole oral suspensi...
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Original Article Source Type: research
Aziz Nazha, MD from the Cleveland Clinic discusses predicting Survival Myelodysplastic Syndrome and using the Random Survival Forest Algorithm at the 2017 American Society of Hematology. Author: ASHReport Added: 01/11/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Conditions:   Myelodysplastic Syndromes;   Myeloproliferative Neoplasm;   Acute Myeloid Leukemia Interventions:   Drug: Azacitidine;   Drug: Ascorbic acid Sponsor:   Case Comprehensive Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In this study, the combination of chidamide (50 nM) with cytarabine (50 nM) showed synergistic inhibition on cell growth.The mean combination index values were 0.068, 0.158, and 0.226 in SKM-1, MUTZ-1, and KG-1 MDS cell lines, respectively. The combination increased the acetylation levels of histone H3 and decreased HDAC activity in MDS cells.A low concentration (25 and 50 nM) of chidamide combined with low-dose cytarabine (50 nM) inhibited cell proliferation and arrested the cell cycle in the G0/G1 phasevia down-regulating CDK2 and up-regulating p21. Furthermore, the combined treatment induced cell apoptosis via down-regu...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
More News: Cancer & Oncology | Hematology | Myelodysplastic Syndrome